The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma

Journal of Surgical Oncology

Volumn 105, Issue 8, 2012, Pages 756-760

  Akutsu, Yasunori ^a   Shuto, Kiyohiko ^a   Kono, Tsuguaki ^a   Uesato, Masaya ^a   Hoshino, Isamu ^a   Shiratori, Toru ^a   Isozaki, Yuka ^a   Akanuma, Naoki ^a   Uno, Takashi ^a   Matsubara, Hisahiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

chemoradiotherapy; esophageal cancer; neoadjuvant therapy; number of lymph nodes; squamous cell carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HAZARD RATIO; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84861095001     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23007     Document Type: Article

References (30)

1. Akutsu Y, Matsubara H:, Perioperative management for the prevention of postoperative pneumonia with esophageal surgery. Ann Thorac Cardiovasc Surg 2009; 15: 280-285.
2. Akutsu Y, Matsubara H, Shuto K, et al.: Pre-operative dental brushing can reduce the risk of postoperative pneumonia in esophageal cancer patients. Surgery 2010; 147: 497-502.
3. Hirst J, Smithers BM, Gotley DC, et al.: Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy. Ann Surg Oncol 2011; 18: 1766-1774.
4. Imamura Y, Hayashi N, Sato N, et al.: Extensive lymphatic spread of cancer cells in patients with thoracic esophageal squamous cell carcinoma: Detection of CEA-mRNA in the three-field lymph nodes. J Surg Oncol 2010; 102: 509-515.
5. Shimada H, Okazumi S, Shiratori T, et al.: Impact of lymph node involvement in T2 or T3 thoracic esophageal squamous cell carcinoma. Hepatogastroenterology 2009; 56: 1039-1043.
6. Hsu WH, Hsu PK, Hsieh CC, et al.: The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer. J Gastrointest Surg 2009; 13: 1913-1920.
7. Akutsu Y, Matsubara H:, The significance of lymph node status as a prognostic factor for esophageal cancer. Surg Today 2011; 41: 1190-1195.
8. Natsugoe S, Matsumoto M, Okumura H, et al.: Clinical course and outcome after esophagectomy with three-field lymphadenectomy in esophageal cancer. Langenbecks Arch Surg 2010; 395: 341-346.
9. Toh Y, Oki E, Minami K, et al.: Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: The first indicators for recurrence and their prognostic values. Esophagus 2010; 7: 37-43.
10. Matsubara H:, Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol 2008; 13: 474-478.
11. Hyngstrom JR, Posner MC:, Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol 2010; 101: 299-304.
12. Rizk NP, Venkatraman E, Bains MS, et al.: American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25: 507-512. (Pubitemid 350002956)
13. Sobin LH, editor: TNM classification of malignant tumours. Hoboken, NJ: John Wiley & Sons, Inc.; 2002.
14. Akutsu Y, Matsubara H, Shuto K, et al.: Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg 2009; 33: 1002-1009.
15. Japan Esophageal Society, editor: Japanese Classification of Esophageal Cancer 10th Edition. Tokyo: Kanehara & Co., Ltd.; 2008.
16. The Registration Committee for Esophageal Cancer JES: Comprehensive Registry of Esophageal Cancer in Japan 2002.
17. Greenstein AJ, Litle VR, Swanson SJ, et al.: Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg 2008; 206: 239-246.
18. Sobin LH, Gospodarowicz MK:, Oesophagus including oesophagogastric junction (ICD-0 C15). In:, Wittekind C, editor. TNM Classification of Malignant Tumours (Uicc International Union Against Cancer). Hoboken, NJ: Wiley-Blackwell Publishing Ltd.; 2009.
19. Edge SB, Byrd DR:, Part III. Digestive system.-Esophagus and esophagogastric junction. In:, Compton CC, editor: AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.
20. Zhang HL, Chen LQ, Liu RL, et al.: The number of lymph node metastases influences survival and International Union against cancer tumor-node-metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus 2010; 23: 53-58.
21. Nabeya Y, Ochiai T, Matsubara H, et al.: Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis. Dis Esophagus 2005; 18: 388-397. (Pubitemid 43904767)
22. Gu Y, Swisher SG, Ajani JA, et al.: The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006; 106: 1017-1025.
23. Gaca JG, Petersen RP, Peterson BL, et al.: Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol 2006; 13: 340-346. (Pubitemid 43255917)
24. Miyata H, Yamasaki M, Takiguchi S, et al.: Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation. Oncol Rep 2010; 23: 1331-1337.
25. Tong DK, Law S, Kwong DL, et al.: Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol 2010; 17: 2184-2192.
26. Donahue JM, Nichols FC, Li Z, et al.: Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009; 87: 392-398 discussion 398-399.
27. Sanchez-Pernaute A, Perez Aguirre E, Hernando Trancho F, et al.: Recurrence pattern of esophageal cancer after esophagectomy with two-field lymphadenectomy. Rev Esp Enferm Dig 2003; 95: 197-201 191-196. (Pubitemid 36534460)
28. Nakagawa S, Kanda T, Kosugi S, et al.: Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004; 198: 205-211. (Pubitemid 38175235)
29. Pifarre-Montaner P, Fernandez-Leon A, de Juan R, et al.: Impact of (18)F-FDG PET/CT on the therapeutic management in the initial staging of the esophageal cancer. Rev Esp Med Nucl 2009; 28: 101-105.
30. Pultrum BB, van der Jagt EJ, van Westreenen HL, et al.: Detection of lymph node metastases with ultrasmall superparamagnetic iron oxide (USPIO)-enhanced magnetic resonance imaging in oesophageal cancer: A feasibility study. Cancer Imaging 2009; 9: 19-28.